Immunotherapy of Hepatocellular Carcinoma

Professor Tim F. Greten has received his training in Gastroenterology, Hepatology and Medical Oncology. He has been treating patients with hepatocellular carcinoma (HCC) for many years has been leading a number of clinical trials. Apart from his clinical expertise Professor Greten has been interested in the immunological aspects of HCC for more than 20 years. He is conducting basic research studies, which he published in the very top scientific journals including Nature, and Cancer Cell and is also a pioneer in immunotherapy studies in HCC. He published a number of different clinical trials testing different immune based approaches in HCC. Based on this medical and basic science background is considered on the world leaders in tumor immunology and immunotherapy of HCC.

• Preface.- Introduction.- Vaccine approaches.- Spontaneous Immune responses to ablative therapies.- Antigen-specific T cell responses. Immune checkpoint inhibitors.- NASH and HCC.- Cytokine activated killer cells.- Sorafenib combination therapy.- Glypican 3.- Suppressor cells.- Cytokines in HCC pathogenesis and treatment.- Index.